RNAi Gene Therapy to Inhibit STMN1 for Solid Tumor is under clinical development by Gradalis and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect RNAi Gene Therapy to Inhibit STMN1 for Solid Tumor’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 27 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their RNAi Gene Therapy to Inhibit STMN1 for Solid Tumor Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

RNAi Gene Therapy to Inhibit STMN1 for Solid Tumor overview

RNAi gene therapy is under development for the treatment of solid tumor. The drug candidate is administered by intratumoral injection. The therapeutic candidate is a RNA interference construct consisting of bifunctional short hairpin RNAs (shRNA) against human stathmin 1 (STMN1) encapsulated in the cationic bilamellar invaginated vesicle lipoplex (LP) with potential antineoplastic activity.

Gradalis overview

Gradalis formerly Murex Pharmaceuticals is a biotechnology company that develops and commercializes novel therapies for the treatment of cancer. The company’s product pipeline includes autologous cancer vaccines, IO combinations and genes proteins for treating Ewing’s sarcoma, ovarian, breast, melanoma, solid tumors, lung, hepatocellular and colorectal cancer. Its proprietary immunotherapy platform, vigil is utilized in various advanced cancer indications and helps in stimulating and improving the body’s natural mechanism for identifying and killing cancer cells. Gradalis is headquartered in Carrollton, Texas, the US.

Quick View RNAi Gene Therapy to Inhibit STMN1 for Solid Tumor LOA Data

Report Segments
  • Innovator
Drug Name
  • RNAi Gene Therapy to Inhibit STMN1 for Solid Tumor
Administration Pathway
  • Intratumor
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.